Journal Article Review Epublish 13 citations
PubMed: 36982210 DOI: 10.3390/ijms24065113
Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature.
Int J Mol Sci 24(6)
Authors: Jakub Wnuk, Joanna Katarzyna Strzelczyk, Iwona Gisterek
Affiliations
- Department of Oncology and Radiotherapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 35 Ceglana St. 40-515 Katowice, Poland.
- Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St. 41-808 Zabrze, Poland.
Abstract
Pancreatic cancer (PC) is considered to be the seventh most common cause of cancer-related deaths. The number of deaths caused by PC is estimated to increase in the future. An early diagnosis of PC is crucial for improving treatment outcomes. The most common histopathological subtype of PC is pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miRNAs)-which are endogenous non-coding RNAs involved in the posttranscriptional regulation of multiple gene expression-constitute useful diagnostic and prognostic biomarkers in various neoplasms, including PDAC. Circulating miRNAs detected in a patient's serum or plasma are drawing more and more attention. Hence, this review aims at evaluating the clinical value of circulating miRNA in the screening, diagnosis, prognosis and monitoring of pancreatic ductal adenocarcinoma therapy.
MeSH
Diagnosis, Adenocarcinoma, Prognosis, Therapeutics, Pancreatic Neoplasms, Micrornas
Cited by
- Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther, 2024
- Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma. Curr Issues Mol Biol, 2025
- MicroRNA Gets a Mighty Award. Adv Sci (Weinh), 2025
- Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics". Int J Mol Sci, 2024
- Tracing the history of clinical practice of liquid biopsy: a bibliometric analysis. Front Immunol, 2025
- Role and potential mechanisms of miR‑100 in different diseases (Review). Oncol Rep, 2025
- Circulating miRNAs as Noninvasive Biomarkers for PDAC Diagnosis and Prognosis in Mexico. Int J Mol Sci, 2023
- Diagnostic Utility of MicroRNAs in Pancreatic Cancers. Cancers (Basel), 2024
- Ultrasound as a New Method for the Release and Identification of Novel microRNAs and Proteins as Candidate Biomarkers in Pancreatic Cancer. Cancers (Basel), 2025
- Multi-omics profiling to identify early plasma biomarkers in pre-diagnostic pancreatic ductal adenocarcinoma: a nested case-control study. Transl Oncol, 2024